Abstract
Chondromodulin-I (ChM-I) was previously identified as an angiogenesis inhibitor in cartilage. Here, we demonstrated that the level of ChM-I transcripts was substantially reduced to 100 or even less in the lower-grade chondrosarcomas, in articular cartilage or other benign cartilage tumors. We implanted human chondrosarcoma OUMS-27 cells into nude mice that reproducibly produced tumors with cartilaginous matrix. Tumor-induced angiogenesis was evident when the tumors were excised 30 days after implantation. However, the local administration of recombinant human ChM-I almost completely blocked vascular invasion and tumor growth in vivo. Moreover, ChM-I also inhibited the growth of HT-29 colon adenocarcinoma in vivo, implying its therapeutic potential for solid tumors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Bone Neoplasms / blood supply
-
Bone Neoplasms / genetics*
-
Bone Neoplasms / pathology
-
Cartilage / pathology
-
Chondrosarcoma / blood supply
-
Chondrosarcoma / genetics*
-
Chondrosarcoma / pathology
-
Gene Expression Regulation, Neoplastic
-
Growth Substances / analysis
-
Growth Substances / pharmacology*
-
HT29 Cells
-
Humans
-
Intercellular Signaling Peptides and Proteins*
-
Membrane Proteins*
-
Mice
-
Mice, Nude
-
Neoplasm Transplantation
-
Neovascularization, Pathologic / pathology*
-
RNA, Messenger / metabolism
-
Recombinant Proteins / pharmacology
-
Tumor Cells, Cultured
Substances
-
Antineoplastic Agents
-
Cnmd protein, mouse
-
Growth Substances
-
Intercellular Signaling Peptides and Proteins
-
Membrane Proteins
-
RNA, Messenger
-
Recombinant Proteins
-
CNMD protein, human